Scott Chan

Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.

Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.

Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.

Analyst Articles

Buy Synchrony Financial (NYSE: SYF) Today we are following the lead of two “oracles.” Both the Oracle of Omaha Warren Buffett and the Oracle of Boston Seth Klarman have bet big on Synchrony Financial (NYSE: SYF). Buffett’s Berkshire Hathaway (NYSE: BRK.B) owns 17.5 million shares Klarman’s Baupost Group owns 29.3… Read More

ViaSat (Nasdaq: VSAT) has completed the Critical Design Review (CDR) for its ViaSat-3 class spacecraft, and is ready to move to the building, integration and testing phase for the first two (of three) satellites to be deployed. The company will once again work with Boeing (NYSE: BA) to build the… Read More

New pick Jazz Pharmaceuticals (Nasdaq: JAZZ) specializes in treating ailments related to sleep disorders and has an expanding portfolio focused on cancers of the blood. The shares are modestly valued by the market, and offer interesting potential upside. Read on for more details. Read More

Sell BYD Company (OTCMKTS: BYDDF). BYD Company (OTCMKTS: BYDDF) has caught fire since a Chinese official revealed that China was considering a timetable for phasing out cars that run on fossil fuels entirely. While we like BYD, the largest electric-car maker in the world, in the long run, in the… Read More

Buy Jazz Pharmaceuticals (Nasdaq: JAZZ) We are adding to our portfolio the top holding in Cadian Capital Management, a hedge fund with about $3 billion in asset under management. Cadian owns 1.39 million shares of Jazz Pharmaceuticals (Nasdaq: JAZZ), making it the largest holding in Cadian’s equity portfolio, with a… Read More

Last Friday we highlighted BYD Company (OTCMKTS: BYDDF) as a buying opportunity as it traded around $6 a share. Our timing could not have been better: a day later, the vice minister of China’s Ministry of Industry and Information Technology stated that the Chinese government is working on a timetable… Read More

BYD Company (OTCMKTS: BYDDF) briefly fell below $6 per share earlier this week before rebounding a bit. Since reaching a 3-month peak in late July, the shares have been under some pressure. Let’s take a look at how the company is faring. In the first half of 2017, BYD had… Read More